Amalgamated Bank Sage Therapeutics, Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

A detailed history of Amalgamated Bank transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,783 shares of SAGE stock, worth $9,770. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,783

Previous 1,783 -0.0%

Holding current value

$9,770

Previous $19,000 31.58%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$18.62 - $26.95 $102,801 - $148,790	-5,521 Reduced 75.59%	1,783 $33,000
Q4 2023 Feb 06, 2024	SELL	$17.1 - $22.26 $9,063 - $11,797	-530 Reduced 6.77%	7,304 $158,000
Q2 2023 Aug 11, 2023	BUY	$40.65 - $59.54 $96,625 - $141,526	2,377 Added 43.56%	7,834 $368,000
Q1 2023 May 02, 2023	SELL	$37.27 - $46.57 $56,165 - $70,180	-1,507 Reduced 21.64%	5,457 $229,000
Q4 2022 Feb 10, 2023	BUY	$32.2 - $43.61 $7,567 - $10,248	235 Added 3.49%	6,964 $266,000
Q3 2022 Nov 09, 2022	BUY	$32.28 - $43.27 $5,003 - $6,706	155 Added 2.36%	6,729 $264,000
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $66,158 - $91,327	-2,404 Reduced 26.78%	6,574 $212,000
Q1 2022 Jun 30, 2022	SELL	$30.71 - $45.71 $9,550 - $14,215	-311 Reduced 3.35%	8,978 $297,000
Q4 2021 Feb 15, 2022	SELL	$37.06 - $47.11 $287,770 - $365,809	-7,765 Reduced 45.53%	9,289 $395,000
Q3 2021 Oct 29, 2021	SELL	$40.26 - $57.37 $19,687 - $28,053	-489 Reduced 2.79%	17,054 $756,000
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $621,406 - $897,800	11,323 Added 182.04%	17,543 $997,000
Q1 2021 May 13, 2021	SELL	$70.65 - $96.76 $31,015 - $42,477	-439 Reduced 6.59%	6,220 $466,000
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $992 - $1,514	-17 Reduced 0.25%	6,659 $576,000
Q3 2020 Oct 30, 2020	SELL	$41.13 - $62.45 $82 - $124	-2 Reduced 0.03%	6,676 $408,000
Q2 2020 Aug 10, 2020	SELL	$25.95 - $43.15 $172,437 - $286,731	-6,645 Reduced 49.88%	6,678 $278,000
Q1 2020 May 13, 2020	SELL	$26.15 - $77.24 $5,962 - $17,610	-228 Reduced 1.68%	13,323 $383,000
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $55,425 - $142,543	921 Added 7.29%	13,551 $978,000
Q3 2019 Nov 13, 2019	BUY	$140.29 - $189.96 $208,611 - $282,470	1,487 Added 13.34%	12,630 $1.77 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $15,627 - $18,125	99 Added 0.9%	11,143 $2.04 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $78,253 - $143,357	876 Added 8.62%	11,044 $1.76 Million
Q4 2018 Feb 15, 2019	BUY	$81.94 - $139.71 $322,024 - $549,060	3,930 Added 63.0%	10,168 $974,000
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $605,336 - $740,902	-4,383 Reduced 41.27%	6,238 $881,000
Q2 2018 Jul 18, 2018	BUY	$140.36 - $175.76 $701,519 - $878,448	4,998 Added 88.88%	10,621 $1.66 Million
Q1 2018 May 22, 2018	BUY	$152.15 - $192.33 $72,423 - $91,549	476 Added 9.25%	5,623 $906,000
Q4 2017 Feb 13, 2018	BUY	$60.72 - $167.34 $45,175 - $124,500	744 Added 16.9%	5,147 $848,000
Q3 2017 Nov 09, 2017	BUY	$61.4 - $88.52 $270,344 - $389,753	4,403	4,403 $274,000

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Sage Therapeutics, Inc. Transaction History